Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JQN1 | ISIN: US76029N1063 | Ticker-Symbol: 7R8
Tradegate
04.06.25 | 21:00
8,500 Euro
0,00 % 0,000
1-Jahres-Chart
REPLIMUNE GROUP INC Chart 1 Jahr
5-Tage-Chart
REPLIMUNE GROUP INC 5-Tage-Chart
RealtimeGeldBriefZeit
8,4508,60011:17
8,4008,60007:30

Aktuelle News zur REPLIMUNE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
REPLIMUNE Aktie jetzt für 0€ handeln
DiJPMorgan reiterates overweight rating on Replimune stock after ASCO9
DiJPMorgan bekräftigt Übergewichtung für Replimune-Aktie nach ASCO5
MoPiper Sandler raises Replimune stock price target after updates4
SoReplimune Group Inc: Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting2
22.05.Replimune Group, Inc. - 10-K, Annual Report4
22.05.Replimune Group, Inc. - 8-K, Current Report4
22.05.Replimune Group GAAP EPS of -$3.07 misses by $0.013
16.05.Replimune Group Inc: Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day3
09.05.Replimune Group Inc: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)93WOBURN, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...
► Artikel lesen
25.04.Replimune Group, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
11.04.Replimune Group Inc: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)156WOBURN, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
► Artikel lesen
14.03.Replimune Group, Inc. - S-8, Securities to be offered to employees in employee benefit plans5
07.03.Replimune Group Inc: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)252WOBURN, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
► Artikel lesen
07.03.Replimune Group, Inc. - 8-K, Current Report3
12.02.Replimune Group, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
12.02.Replimune Group GAAP EPS of -$0.79 misses by $0.071
12.02.Replimune Group, Inc. - 10-Q, Quarterly Report1
12.02.Replimune Group, Inc. - 8-K, Current Report-
07.02.Replimune Group Inc: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)198WOBURN, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...
► Artikel lesen
22.01.Replimune Group, Inc. - 8-K, Current Report1
Seite:  Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1